A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
A phase 3, multicenter, randomized, double-blind, double-dummy, parallel-group, active-drug- and placebo-controlled clinical trial to assess the safety, efficacy and superiority of the new fixed-dose combination sibutramine IR/topyramat XR in weight reduction in overweight adults with comorbidity(ies) or obesity
Epistemonikos ID: ae09cb29f4a07209fabe49204fb7c577bc77a31a
First added on: May 10, 2024